CA125 in Ovarian Tumour Tissue at Second Laparotomy
Author Information
Author(s): T.S. Maughan, R.G. Fish, M.D. Shelley, B. Jasani, G.T. Williams, M. Adams
Primary Institution: South Wales Radiotherapy and Oncology Service, Velindre Hospital
Hypothesis
The study investigates the presence of CA125 in ovarian tumour tissue and its correlation with residual disease after chemotherapy.
Conclusion
CA125 was detected in tumour tissue of all patients, even when serum levels were normal, indicating that normal serum CA125 levels do not necessarily reflect the absence of residual disease.
Supporting Evidence
- CA125 was present in the tumour tissue of over 80% of ovarian carcinomas at first laparotomy.
- Serum CA125 levels were elevated in over 60% of patients and correlated with the clinical course of the disease.
- Normal serum CA125 levels after chemotherapy do not rule out the presence of residual disease.
Takeaway
Doctors looked at a special marker called CA125 in the tissue of women with ovarian cancer to see if it could help find leftover cancer after treatment, and they found it was still there even when blood tests said it wasn't.
Methodology
The study assessed CA125 levels in tumour tissue from patients at first and second laparotomies using immunohistochemical techniques.
Limitations
The study does not address the reasons for false-negative serum CA125 results in patients with residual disease.
Participant Demographics
Mean age of participants was 52.7 years, all had residual tumour after first laparotomy.
Want to read the original?
Access the complete publication on the publisher's website